Harrell W Chesson1, Jean-François Laprise2, Marc Brisson3, Lauri E Markowitz1. 1. Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. Centre de recherche du CHU de Québec, Université Laval, Axe Santé des populations et pratiques optimales en santé 3. Centre de recherche du CHU de Québec, Université Laval, Axe Santé des populations et pratiques optimales en santé Département de médecine sociale et préventive, Université Laval, Québec, Canada Department of Infectious Disease Epidemiology, Imperial College, London, United Kingdom.
Abstract
BACKGROUND: We estimated the potential impact and cost-effectiveness of providing 3-doses of nonavalent human papillomavirus (HPV) vaccine (9vHPV) to females aged 13-18 years who had previously completed a series of quadrivalent HPV vaccine (4vHPV), a strategy we refer to as "additional 9vHPV vaccination." METHODS: We used 2 distinct models: (1) the simplified model, which is among the most basic of the published dynamic HPV models, and (2) the US HPV-ADVISE model, a complex, stochastic, individual-based transmission-dynamic model. RESULTS: When assuming no 4vHPV cross-protection, the incremental cost per quality-adjusted life-year (QALY) gained by additional 9vHPV vaccination was $146 200 in the simplified model and $108 200 in the US HPV-ADVISE model ($191 800 when assuming 4vHPV cross-protection). In 1-way sensitivity analyses in the scenario of no 4vHPV cross-protection, the simplified model results ranged from $70 300 to $182 000, and the US HPV-ADVISE model results ranged from $97 600 to $118 900. CONCLUSIONS: The average cost per QALY gained by additional 9vHPV vaccination exceeded $100 000 in both models. However, the results varied considerably in sensitivity and uncertainty analyses. Additional 9vHPV vaccination is likely not as efficient as many other potential HPV vaccination strategies, such as increasing primary 9vHPV vaccine coverage. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: We estimated the potential impact and cost-effectiveness of providing 3-doses of nonavalent human papillomavirus (HPV) vaccine (9vHPV) to females aged 13-18 years who had previously completed a series of quadrivalent HPV vaccine (4vHPV), a strategy we refer to as "additional 9vHPV vaccination." METHODS: We used 2 distinct models: (1) the simplified model, which is among the most basic of the published dynamic HPV models, and (2) the US HPV-ADVISE model, a complex, stochastic, individual-based transmission-dynamic model. RESULTS: When assuming no 4vHPV cross-protection, the incremental cost per quality-adjusted life-year (QALY) gained by additional 9vHPV vaccination was $146 200 in the simplified model and $108 200 in the US HPV-ADVISE model ($191 800 when assuming 4vHPV cross-protection). In 1-way sensitivity analyses in the scenario of no 4vHPV cross-protection, the simplified model results ranged from $70 300 to $182 000, and the US HPV-ADVISE model results ranged from $97 600 to $118 900. CONCLUSIONS: The average cost per QALY gained by additional 9vHPV vaccination exceeded $100 000 in both models. However, the results varied considerably in sensitivity and uncertainty analyses. Additional 9vHPV vaccination is likely not as efficient as many other potential HPV vaccination strategies, such as increasing primary 9vHPV vaccine coverage. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Marc Brisson; Jean-François Laprise; Mélanie Drolet; Nicolas Van de Velde; Eduardo L Franco; Erich V Kliewer; Gina Ogilvie; Shelley L Deeks; Marie-Claude Boily Journal: Vaccine Date: 2013-07-03 Impact factor: 3.641
Authors: Harrell W Chesson; Lauri E Markowitz; Susan Hariri; Donatus U Ekwueme; Mona Saraiya Journal: Hum Vaccin Immunother Date: 2016-02-18 Impact factor: 3.452
Authors: Elmar A Joura; Anna R Giuliano; Ole-Erik Iversen; Celine Bouchard; Constance Mao; Jesper Mehlsen; Edson D Moreira; Yuen Ngan; Lone Kjeld Petersen; Eduardo Lazcano-Ponce; Punnee Pitisuttithum; Jaime Alberto Restrepo; Gavin Stuart; Linn Woelber; Yuh Cheng Yang; Jack Cuzick; Suzanne M Garland; Warner Huh; Susanne K Kjaer; Oliver M Bautista; Ivan S F Chan; Joshua Chen; Richard Gesser; Erin Moeller; Michael Ritter; Scott Vuocolo; Alain Luxembourg Journal: N Engl J Med Date: 2015-02-19 Impact factor: 91.245
Authors: Susan Hariri; Elizabeth R Unger; Sean Schafer; Linda M Niccolai; Ina U Park; Karen C Bloch; Nancy M Bennett; Martin Steinau; Michelle L Johnson; Lauri E Markowitz Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-11-21 Impact factor: 4.254
Authors: Nicolas Van de Velde; Marie-Claude Boily; Mélanie Drolet; Eduardo L Franco; Marie-Hélène Mayrand; Erich V Kliewer; François Coutlée; Jean-François Laprise; Talía Malagón; Marc Brisson Journal: J Natl Cancer Inst Date: 2012-10-27 Impact factor: 13.506
Authors: Jean-François Laprise; Harrell W Chesson; Lauri E Markowitz; Mélanie Drolet; Dave Martin; Élodie Bénard; Marc Brisson Journal: Ann Intern Med Date: 2019-12-10 Impact factor: 25.391
Authors: Kathleen L Dooling; Angela Guo; Manisha Patel; Grace M Lee; Kelly Moore; Edward A Belongia; Rafael Harpaz Journal: MMWR Morb Mortal Wkly Rep Date: 2018-01-26 Impact factor: 17.586
Authors: C Signorelli; A Odone; V Ciorba; P Cella; R A Audisio; A Lombardi; L Mariani; F S Mennini; S Pecorelli; G Rezza; G V Zuccotti; A Peracino Journal: Epidemiol Infect Date: 2017-04-27 Impact factor: 4.434